As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
Additives and ingredients: Some patients find that certain nonnutritive sweeteners, sugar alcohols (sorbitol, maltitol), or other additives may trigger gastrointestinal distress
It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication
No office visit needed for shipping RX
It lowers blood sugar levels, improves insulin sensitivity, and may support weight loss
Following general guidelines about brushing and flossing and visiting a dentist can help ward off these side effects, which generally resolve over time.